Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormonesensitive prostate cancer (mHSPC): A public payer perspective using network metaanalysis

被引：0
|
作者：
Kohli, Manish
Dougherty, Maura
Cutshall, Zachary
Beckstead, Rylee
Kohli, Rhea
Haaland, Benjamin
Nelson, Richard
Yoo, Minkyoung
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5081
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Shiroiwa, Takeru
    Fukuda, Takashi
    Tsutani, Kiichiro
    CLINICAL THERAPEUTICS, 2007, 29 (10) : 2256 - 2267
  • [42] Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a US Payer's Perspective
    Nguyen, Chi
    Lairson, David R.
    Swartz, Michael D.
    Du, Xianglin L.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (02): : 225 - 234
  • [43] COST EFFECTIVENESS ANALYSIS OF LEUPROLIDE VERSUS GOSERELIN IN THE TREATMENT OF METASTATIC PROSTATE CANCER IN THE BAHAMAS
    Sakharkar, P.
    Danaah, M. M.
    VALUE IN HEALTH, 2013, 16 (03) : A140 - A140
  • [44] Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
    Wang, Yingcheng
    Rui, Mingjun
    Guan, Xin
    Cao, Yingdan
    Chen, Pingyu
    FRONTIERS IN MEDICINE, 2021, 8
  • [45] Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer
    Adekunle, Olajide A.
    Seoane-Vazquez, Enrique
    Brown, Lawrence M.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2023, 63 (03) : 817 - 824.e3
  • [46] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Holanda, P.
    Salgado De Santana, C.
    Senna, T.
    Carmo, L.
    Alexandre, R. F.
    VALUE IN HEALTH, 2021, 24 : S96 - S96
  • [47] New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
    Wilson, Leslie
    Tang, Jun
    Zhong, Lixian
    Balani, Gregory
    Gipson, Gregory
    Xiang, Pin
    Yu, Dawn
    Srinivas, Sandy
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (06) : 417 - 425
  • [48] Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis.
    Zhong, Lixian
    Srinivas, Sandy
    Pon, Vickie
    Nicole Nguyen
    Frear, Meghan
    Kwan, Sherry
    Gong, Cynthia
    Malmstrom, Robert
    Loucks, Aimee
    Wilson, Leslie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE AND SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Gong, C. L.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A82 - A83
  • [50] Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system
    Ying, Ting
    Xia, Runan
    Zhang, Yuanyuan
    Dai, Jiahui
    Wang, Yadong
    Xie, Xuefeng
    BMJ OPEN, 2024, 14 (11):
12345